Innoviva, Inc. (INVA) stock
INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3039% below fair value
$18.30−0.19 (-1.03%)
Close on Nov 17, 2026Market cap $1.32BP/E 9.3Yield –
Innoviva total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Innoviva's total debt was $258.82M at Sep 30, 2026. For fiscal 2025 it was $257.73M, down 42.5% from the year before. Over ten years it grew -9.9% a year on average. The highest annual figure on record is $733.13M in fiscal 2015.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $257.73M | -42.5% |
| FY2024 | Dec 31, 2024 | $448.34M | +0.5% |
| FY2023 | Dec 31, 2023 | $446.23M | -17.4% |
| FY2022 | Dec 31, 2022 | $540.37M | +36.9% |
| FY2021 | Dec 31, 2021 | $394.65M | +2.4% |
| FY2020 | Dec 31, 2020 | $385.52M | +2.2% |
| FY2019 | Dec 31, 2019 | $377.12M | -1.5% |
| FY2018 | Dec 31, 2018 | $382.86M | -33.3% |
| FY2017 | Dec 31, 2017 | $574.36M | -19.8% |
| FY2016 | Dec 31, 2016 | $716.09M | -2.3% |
| FY2015 | Dec 31, 2015 | $733.13M | +1.0% |
| FY2014 | Dec 31, 2014 | $725.64M | +152.4% |
| FY2013 | Dec 31, 2013 | $287.50M | +416566.7% |
| FY2011 | Dec 31, 2011 | $69.00K | -74.9% |
| FY2010 | Dec 31, 2010 | $275.00K | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $258.82M | +0.6% |
| Q2 FY2026 | Jun 30, 2026 | $258.45M | -42.4% |
| Q1 FY2026 | Mar 31, 2026 | $258.10M | -42.5% |
| Q4 FY2025 | Dec 31, 2025 | $257.73M | -42.5% |
| Q3 FY2025 | Sep 30, 2025 | $257.38M | -42.5% |
| Q2 FY2025 | Jun 30, 2025 | $448.92M | +0.4% |
| Q1 FY2025 | Mar 31, 2025 | $448.89M | +0.5% |
| Q4 FY2024 | Dec 31, 2024 | $448.34M | +0.5% |
| Q3 FY2024 | Sep 30, 2024 | $447.82M | +0.5% |
| Q2 FY2024 | Jun 30, 2024 | $447.28M | +0.5% |
| Q1 FY2024 | Mar 31, 2024 | $446.76M | +0.5% |
| Q4 FY2023 | Dec 31, 2023 | $446.23M | -17.4% |
| Q3 FY2023 | Sep 30, 2023 | $445.72M | -17.4% |
| Q2 FY2023 | Jun 30, 2023 | $445.20M | -17.4% |
| Q1 FY2023 | Mar 31, 2023 | $444.69M | -17.5% |
| Q4 FY2022 | Dec 31, 2022 | $540.37M | +36.9% |
| Q3 FY2022 | Sep 30, 2022 | $539.81M | +37.6% |
| Q2 FY2022 | Jun 30, 2022 | $539.25M | +38.3% |
| Q1 FY2022 | Mar 31, 2022 | $538.75M | +38.9% |
| Q4 FY2021 | Dec 31, 2021 | $394.65M | +2.4% |
| Q3 FY2021 | Sep 30, 2021 | $392.30M | +2.3% |
| Q2 FY2021 | Jun 30, 2021 | $389.99M | +2.3% |
| Q1 FY2021 | Mar 31, 2021 | $387.73M | +2.3% |
| Q4 FY2020 | Dec 31, 2020 | $385.52M | +2.2% |
| Q3 FY2020 | Sep 30, 2020 | $383.35M | -1.4% |
| Q2 FY2020 | Jun 30, 2020 | $381.23M | -1.4% |
| Q1 FY2020 | Mar 31, 2020 | $379.15M | -1.5% |
| Q4 FY2019 | Dec 31, 2019 | $377.12M | -1.5% |
| Q3 FY2019 | Sep 30, 2019 | $388.64M | +2.0% |
| Q2 FY2019 | Jun 30, 2019 | $386.68M | -20.5% |
| Q1 FY2019 | Mar 31, 2019 | $384.74M | -20.6% |
| Q4 FY2018 | Dec 31, 2018 | $382.86M | -33.3% |
| Q3 FY2018 | Sep 30, 2018 | $381.00M | -34.1% |
| Q2 FY2018 | Jun 30, 2018 | $486.53M | -25.6% |
| Q1 FY2018 | Mar 31, 2018 | $484.59M | -31.0% |
| Q4 FY2017 | Dec 31, 2017 | $574.36M | -19.8% |
| Q3 FY2017 | Sep 30, 2017 | $578.45M | – |
| Q2 FY2017 | Jun 30, 2017 | $653.89M | – |
| Q1 FY2017 | Mar 31, 2017 | $702.33M | – |
| Q4 FY2016 | Dec 31, 2016 | $716.09M | – |
See a number that looks wrong?